BR112023003455A2 - Métodos para o tratamento de embolização por cristais de colesterol com ciclodextrinas - Google Patents
Métodos para o tratamento de embolização por cristais de colesterol com ciclodextrinasInfo
- Publication number
- BR112023003455A2 BR112023003455A2 BR112023003455A BR112023003455A BR112023003455A2 BR 112023003455 A2 BR112023003455 A2 BR 112023003455A2 BR 112023003455 A BR112023003455 A BR 112023003455A BR 112023003455 A BR112023003455 A BR 112023003455A BR 112023003455 A2 BR112023003455 A2 BR 112023003455A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- embolization
- cholesterol crystals
- cyclodextrins
- treatment
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 8
- 235000012000 cholesterol Nutrition 0.000 title abstract 4
- 239000013078 crystal Substances 0.000 title abstract 4
- 230000010102 embolization Effects 0.000 title abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 title 1
- 229940097362 cyclodextrins Drugs 0.000 title 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
São divulgados no presente documento métodos para reduzir uma quantidade e/ou um tamanho e/ou alterar o formato de cristais de colesterol (e/ou coágulos que compreendem cristais de colesterol) circulantes (por exemplo, sangue, soro, plasma) em um indivíduo. São adicionalmente divulgados no presente documento métodos de tratamento de embolização por cristais de colesterol (ECC) e/ou um sintoma da mesma em um indivíduo. Os métodos envolvem, de modo geral, administrar uma quantidade terapeuticamente eficaz de 2-hidroxipropil-beta-ciclodextrina ao indivíduo. São adicionalmente fornecidas, no presente documento, composições farmacêuticas que compreendem uma quantidade terapeuticamente eficaz de 2-hidroxipropil-beta-ciclodextrina e um excipiente farmaceuticamente aceitável.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063071222P | 2020-08-27 | 2020-08-27 | |
| PCT/US2021/048072 WO2022047241A1 (en) | 2020-08-27 | 2021-08-27 | Methods for the treatment of cholesterol crystal embolization with cyclodextrins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023003455A2 true BR112023003455A2 (pt) | 2023-05-02 |
Family
ID=80353289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023003455A BR112023003455A2 (pt) | 2020-08-27 | 2021-08-27 | Métodos para o tratamento de embolização por cristais de colesterol com ciclodextrinas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230330133A1 (pt) |
| EP (1) | EP4203972A1 (pt) |
| JP (1) | JP2023543133A (pt) |
| KR (1) | KR20230096975A (pt) |
| CN (1) | CN116322643A (pt) |
| AU (1) | AU2021333902A1 (pt) |
| BR (1) | BR112023003455A2 (pt) |
| CA (1) | CA3190563A1 (pt) |
| IL (1) | IL300806A (pt) |
| MX (1) | MX2023002419A (pt) |
| WO (1) | WO2022047241A1 (pt) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4877778A (en) * | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
| MX371073B (es) * | 2012-04-13 | 2020-01-15 | L&F Res Llc | Método para utilizar ciclodextrina. |
-
2021
- 2021-08-27 AU AU2021333902A patent/AU2021333902A1/en active Pending
- 2021-08-27 KR KR1020237010389A patent/KR20230096975A/ko unknown
- 2021-08-27 BR BR112023003455A patent/BR112023003455A2/pt unknown
- 2021-08-27 CA CA3190563A patent/CA3190563A1/en active Pending
- 2021-08-27 CN CN202180053198.8A patent/CN116322643A/zh active Pending
- 2021-08-27 MX MX2023002419A patent/MX2023002419A/es unknown
- 2021-08-27 US US18/043,013 patent/US20230330133A1/en active Pending
- 2021-08-27 JP JP2023513682A patent/JP2023543133A/ja active Pending
- 2021-08-27 EP EP21862876.6A patent/EP4203972A1/en active Pending
- 2021-08-27 WO PCT/US2021/048072 patent/WO2022047241A1/en unknown
- 2021-08-27 IL IL300806A patent/IL300806A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021333902A1 (en) | 2023-03-16 |
| WO2022047241A1 (en) | 2022-03-03 |
| US20230330133A1 (en) | 2023-10-19 |
| CN116322643A (zh) | 2023-06-23 |
| IL300806A (en) | 2023-04-01 |
| EP4203972A1 (en) | 2023-07-05 |
| MX2023002419A (es) | 2023-07-11 |
| KR20230096975A (ko) | 2023-06-30 |
| JP2023543133A (ja) | 2023-10-13 |
| CA3190563A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fuji et al. | Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin | |
| Sakallioglu et al. | The efficacy of tranexamic acid and corticosteroid on edema and ecchymosis in septorhinoplasty | |
| May et al. | The assessment of blood loss during total knee arthroplasty when comparing intravenous vs intracapsular administration of tranexamic acid | |
| Mei et al. | The efficacy of tranexamic acid for orthognathic surgery: a meta-analysis of randomized controlled trials | |
| BRPI0411906A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos | |
| Ho et al. | Open reduction and internal fixation of acute intra-articular displaced calcaneal fractures: a retrospective analysis of surgical timing and infection rates | |
| BR112022011951A2 (pt) | Tratamento de esclerose lateral amiotrófica e distúrbios relacionados | |
| Sapate et al. | To study the effect of injection dexmedetomidine for prevention of pain due to propofol injection and to compare it with injection lignocaine | |
| Zimmerer et al. | Diagnosis and treatment of optic nerve trauma | |
| Eley et al. | Low molecular weight heparin in patients undergoing free tissue transfer following head and neck ablative surgery: review of efficacy and associated complications | |
| Kosucu et al. | Effects of perioperative magnesium sulfate with controlled hypotension on intraoperative bleeding and postoperative ecchymosis and edema in open rhinoplasty | |
| Yorkgitis et al. | Antiplatelet and anticoagulation medications and the surgical patient | |
| Song et al. | Effects of remote ischemic preconditioning in patients with concentric myocardial hypertrophy: A randomized, controlled trial with molecular insights | |
| Tanoğlu et al. | Two-Stage Surgery for the Malleolar Fracture− Dislocation With Severe Soft Tissue Injuries Does Not Affect the Functional Results | |
| BR112023003455A2 (pt) | Métodos para o tratamento de embolização por cristais de colesterol com ciclodextrinas | |
| Wu et al. | Observation on therapeutic efficacy of rt-PA intravenous thrombolysis combined with compound anisodine injection on central retinal artery occlusion | |
| Alimian et al. | Regional vitamin C in Bier block reduces the incidence of CRPS-1 following distal radius fracture surgery | |
| Kim et al. | The efficacy of TachoComb on reducing postoperative complications after tonsillectomy in children | |
| Zhao et al. | Hemostasis in sinus surgery | |
| BR112023003490A2 (pt) | Métodos para prevenção de embolização de cristais de colesterol com ciclodextrinas | |
| Ghiasi et al. | A pilot study of nebulized heparin for prevention of ventilator induced lung injury: comparative effects with an inhaled corticosteroid | |
| JP5456802B2 (ja) | 細胞遊走促進剤及び創傷治療用の経皮吸収剤 | |
| Altunhan et al. | Persistent nasal bleeding due to nasal CPAP application in 2 premature newborns successfully treated with topical “ankaferd blood stopper” | |
| González-Bárcenas et al. | Management of antiplatelet and anticoagulant therapy for endoscopic procedures: Introduction to novel oral anticoagulants | |
| Nelson et al. | Endoscopic craniosynostosis repair |